8-K: SI-BONE Reports Strong Q1 2025 Results, Updates Full-Year Guidance

SI-BONE, Inc. announced a robust first quarter in 2025 with significant revenue growth and positive adjusted EBITDA, leading to an updated and improved full-year revenue guidance.

Summary

• SI-BONE, Inc. reported its financial results for the first quarter of 2025.
• Worldwide revenue reached $47.3 million, a 24.9% increase compared to the same period in 2024.
• U.S. revenue grew by 26.6% to $44.8 million.
• The company's gross margin improved to 79.7%.
• SI-BONE achieved a net loss of $6.5 million, a 40.0% improvement year-over-year.
• Adjusted EBITDA was positive at $0.5 million.
• Cash and equivalents totaled $144.4 million.
• The company updated its 2025 worldwide revenue guidance to a range of $193.5 million to $197.5 million.
• SI-BONE anticipates operating expenses to grow at approximately 10% and expects to deliver positive adjusted EBITDA for the full year 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and updated guidance. The company's performance exceeded expectations, and management's comments are optimistic.

Positives

• SI-BONE experienced significant revenue growth in Q1 2025.
• The company improved its gross margin.
• Net loss decreased substantially compared to the previous year.
• SI-BONE achieved positive adjusted EBITDA.
• The company has a strong cash position.
• The updated revenue guidance for 2025 indicates continued growth.
• The proposed NTAP rule could provide additional revenue.

Negatives

• SI-BONE still reported a net loss of $6.5 million for the quarter.
• International revenue growth was minimal, increasing only slightly from $2.4 million to $2.5 million.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the ability to commercialize new products, maintain favorable reimbursement, and manage supply chain risks.
• Economic conditions and tariffs could impact patient demand for elective procedures.
• Future capital requirements may be driven by new surgical systems requiring instrument tray and implant inventory investment.
• The pace of re-normalization of the healthcare operating environment could affect the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's products.

Future Outlook

SI-BONE expects 2025 worldwide revenue to be in the range of $193.5 million to $197.5 million, with a gross margin of 78%. The company anticipates operating expenses to grow at approximately 10% and expects to deliver positive adjusted EBITDA for the full year 2025.

Management Comments

• Laura Francis, Chief Executive Officer, stated that the company outperformed across all key value creation metrics.
• Laura Francis highlighted the strong revenue growth, expanded gross margins, and exceeded profitability targets.
• Laura Francis noted the rapid progress on the adoption of innovative products.

Industry Context

SI-BONE's focus on sacropelvic disorders positions it in a growing market for minimally invasive surgical solutions. The company's expansion into adjacent markets like adult deformity and pelvic trauma suggests a strategy to diversify its revenue streams and capitalize on its expertise in sacropelvic fixation.

Comparison to Industry Standards

• Comparing SI-BONE's growth to other medical device companies focused on surgical solutions, companies like Stryker and Zimmer Biomet, which are much larger, often see more modest growth rates in the single to low double digits.
• SI-BONE's 25% revenue growth is significant in this context, suggesting strong market adoption of their iFuse technology.
• The positive adjusted EBITDA is a key indicator of improving financial health, as many smaller medical device companies struggle to achieve profitability while scaling.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and updated guidance.
• Employees may benefit from the company's growth and improved financial performance.
• Customers (physicians and patients) will continue to have access to SI-BONE's technologies.
• Suppliers may see increased demand for their products and services.

Next Steps

• SI-BONE will continue to focus on innovation and commercial execution.
• The company will monitor the impact of the proposed NTAP rule.
• SI-BONE will host a conference call to discuss the first quarter 2025 financial results.

Key Dates

Keywords

SI-BONE, revenue, adjusted EBITDA, sacropelvic disorders, iFuse, financial results, medical device, NTAP, growth, gross margin